Retatrutide, a novel dual-acting glucose-responsive incretin mimetic, represents a significant progression in peptide treatments for the management of type 2 diabetic conditions and, increasingly, excess adiposity. Unlike many existing treatment interventions, retatrutide merges the actions of a GLP-1 receptor agonist and a GIP receptor stimulant,